MBX Biosciences to Participate in June Investor Conferences
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced its participation in two major investor conferences in June 2025. CEO Kent Hawryluk will present at the Jefferies Global Healthcare Conference in New York on June 4 at 2:00 p.m. ET, and at the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET. Live webcasts will be available on the company's investor website, with replays accessible for approximately 90 days after the events.
MBX Biosciences (Nasdaq: MBX), un'azienda biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025. Il CEO Kent Hawryluk presenterà alla Jefferies Global Healthcare Conference a New York il 4 giugno alle 14:00 ET, e alla Goldman Sachs Global Healthcare Conference a Miami il 9 giugno alle 10:40 ET. Le dirette webcast saranno disponibili sul sito web per investitori dell'azienda, con le registrazioni accessibili per circa 90 giorni dopo gli eventi.
MBX Biosciences (Nasdaq: MBX), una compañía biofarmacéutica en etapa clínica especializada en terapias peptídicas de precisión para trastornos endocrinos y metabólicos, ha anunciado su participación en dos importantes conferencias para inversores en junio de 2025. El CEO Kent Hawryluk presentará en la Jefferies Global Healthcare Conference en Nueva York el 4 de junio a las 2:00 p.m. ET, y en la Goldman Sachs Global Healthcare Conference en Miami el 9 de junio a las 10:40 a.m. ET. Las transmisiones en vivo estarán disponibles en el sitio web para inversores de la compañía, con repeticiones accesibles durante aproximadamente 90 días después de los eventos.
MBX Biosciences (나스닥: MBX)는 내분비 및 대사 질환을 위한 정밀 펩타이드 치료제를 전문으로 하는 임상 단계 바이오제약 회사로, 2025년 6월에 열리는 두 개의 주요 투자자 컨퍼런스에 참여할 것이라고 발표했습니다. CEO 켄트 하우릴룩(Kent Hawryluk)은 6월 4일 오후 2시(동부시간)에 뉴욕에서 열리는 Jefferies Global Healthcare Conference와 6월 9일 오전 10시 40분(동부시간)에 마이애미에서 열리는 Goldman Sachs Global Healthcare Conference에서 발표할 예정입니다. 라이브 웹캐스트는 회사의 투자자 웹사이트에서 제공되며, 행사 후 약 90일간 다시보기 서비스를 이용할 수 있습니다.
MBX Biosciences (Nasdaq : MBX), une société biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé sa participation à deux grandes conférences pour investisseurs en juin 2025. Le PDG Kent Hawryluk présentera à la Jefferies Global Healthcare Conference à New York le 4 juin à 14h00 ET, ainsi qu'à la Goldman Sachs Global Healthcare Conference à Miami le 9 juin à 10h40 ET. Des webcasts en direct seront disponibles sur le site des investisseurs de la société, avec des rediffusions accessibles pendant environ 90 jours après les événements.
MBX Biosciences (Nasdaq: MBX), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf präzise Peptidtherapien für endokrine und metabolische Erkrankungen spezialisiert hat, gab seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 bekannt. CEO Kent Hawryluk wird am 4. Juni um 14:00 Uhr ET auf der Jefferies Global Healthcare Conference in New York und am 9. Juni um 10:40 Uhr ET auf der Goldman Sachs Global Healthcare Conference in Miami präsentieren. Live-Webcasts sind auf der Investorenseite des Unternehmens verfügbar, mit Wiedergaben, die etwa 90 Tage nach den Veranstaltungen abrufbar sind.
- None.
- None.
CARMEL, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, will present at and participate in the following investor conferences:
Jefferies Global Healthcare Conference
Dates: June 4-5, 2025
Fireside Chat: June 4, 2025, 2:00 p.m. ET
Location: New York, NY
Goldman Sachs Global Healthcare Conference
Date: June 9, 2025
Podium Presentation: June 9, 2025, 10:40 a.m. ET
Location: Miami, FL
The live webcasts can be accessed in the investors section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replays will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; MBX 1416 for the treatment of post-bariatric hypoglycemia (PBH) in Phase 1 development; and an obesity portfolio that includes MBX 4291, with an IND filing anticipated in Q2 2025, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Kati Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When is MBX Biosciences presenting at the Jefferies Global Healthcare Conference 2025?
What time is MBX Biosciences' presentation at the Goldman Sachs Global Healthcare Conference?
Who will be presenting at the upcoming MBX investor conferences?
Where can I access the webcasts of MBX Biosciences' conference presentations?
